SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!
Viral Vectors in Cancer Immunotherapy
- 1st Edition, Volume 379 - August 2, 2023
- Editors: Fernando Aranda Vega, Pedro Berraondo, Lorenzo Galluzzi
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 9 2 4 9 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 9 2 5 0 - 0
Viral Vectors in Cancer Immunotherapy, Volume 379 in the International Review of Cell and Molecular Biology presents the latest on cancer immunotherapy and how it has transformed… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteViral Vectors in Cancer Immunotherapy, Volume 379 in the International Review of Cell and Molecular Biology presents the latest on cancer immunotherapy and how it has transformed cancer treatment through advances in immune checkpoint inhibitors and adoptive cell therapy. Chapters in this new release include Past, present and future of viral vectors in cancer immunotherapy, Alphaviruses in cancer immunotherapy, Adenoviral-based cancer gene therapy, Armored modified vaccinia Ankara in cancer immunotherapy, Strategies of Semliki Forest virus in immuno-oncology, Maraba virus in cancer immunotherapy, Oncolytic viruses in hematological malignancies, Oncolytic virus for cancer therapies: Overview and future directions, and more.
The use of genetically modified viruses allows the expression of pro-inflammatory molecules, while the immune system receives danger signals from the viruses themselves. In some cases, the virus can also induce tumor cell death. This book will review advances in virus-based cancer immunotherapy in both solid tumors and hematologic malignancies.
- Provides an overview of the landscape of virotherapy for solid tumors and hematologic malignancies
- Reviews advances in alphaviruses, adenoviruses, vaccinia viruses and Maraba virus
- Presents lessons on how to improve viruses to enhance immune responses
Professionals working in the area of oncology looking for up-to-date knowledge of newer immune-based therapies
1. Viral Vectors Engineered for Gene Therapy
Kenneth Lundstrom
2. Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity
Noelia Silva-Pilipich, Ángela Covo-Vergara, Lucía Vanrell, and Cristian Smerdou
3. Armored modified vaccinia Ankara in cancer immunotherapy
Cigdem Atay, José Medina-Echeverz, Hubertus Hochrein, Mark Suter, and Maria Hinterberger
4. Alphaviruses in Cancer Immunotherapy
Kenneth Lundstrom
5. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success
Irati Hervás-Corpión and Marta M. Alonso
6. Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies
Mário Sousa-Pimenta, Ângelo Martins, and Vera Machado
7. Oncolytic virotherapy in lung cancer
Estanislao Nistal-Villan, Sergio Rius-Rocabert, and Francisco Llinares-Pinel
8. Rational selection of an ideal oncolytic virus to address current limitations in clinical translation
Rupsa Basu and Chad M. Moles
- No. of pages: 277
- Language: English
- Edition: 1
- Volume: 379
- Published: August 2, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443192494
- eBook ISBN: 9780443192500
FA
Fernando Aranda Vega
Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.
Affiliations and expertise
Fernando Aranda Vega, CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, SpainPB
Pedro Berraondo
Pedro Berraondo graduated in Pharmacy at the University of Navarra in 1999. In 2004 he obtained the Ph.D. at the same university. Next, he worked at the Pasteur Institute in Paris (France) under the supervision of Dr. Claude Leclerc, where he developed novel strategies in tumor immunotherapy within the European THERAVAC project. In February 2007, he joined the Immunology and Immunotherapy Program at the Cima Universidad de Navarra, where he leads the Cytokine-based Immunotherapy laboratory. He is co-inventor of ten patents and he is co-author of more than 140 publications, including publications in Nature, Nature Medicine, Nature Reviews Drug Discovery, Immunity, Cancer Discovery, and Cancer Cell. He was certified as a full professor in 2021 by AQU. He is co-director of the degree of expert in immunooncology at the Faculty of Medicine of the University of Navarra, and is in charge of the undergraduate course of macromolecular structure at the Faculty of Sciences of the University of Navarra. He is also the coordinator of the immuno-oncology work module at CIBERONC.
Affiliations and expertise
CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, SpainLG
Lorenzo Galluzzi
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USARead Viral Vectors in Cancer Immunotherapy on ScienceDirect